Cristina Caramés


Country: Spain


  1. Cristobal I, Torrejón B, Rubio J, Santos A, Pedregal M, Caramés C, et al. Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer. J Clin Med. 2019;8: pubmed publisher
    ..Thus, SET emerges as a novel potential molecular target with clinical impact in early-stage in CRC. ..
  2. Cristobal I, Sanz Alvarez M, Luque M, Caramés C, Rojo F, Garcia Foncillas J. The Role of MicroRNAs in Hepatoblastoma Tumors. Cancers (Basel). 2019;11: pubmed publisher
  3. Madoz Gúrpide J, Zazo S, Chamizo C, Casado V, Caramés C, Gavín E, et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med. 2015;13:282 pubmed publisher
    ..When treated with a cetuximab-based regimen, these patients correlated with worse outcome. This supports a dual blocking strategy of HGF/MET and EGFR pathways for the treatment of patients with recurrent/metastatic HNSCC. ..
  4. Caramés C, Cristobal I, Moreno V, Marín J, González Alonso P, Torrejón B, et al. MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. Int J Mol Sci. 2016;17: pubmed publisher
    ..Altogether, miR-31 quantification emerges as a novel valuable clinical tool to predict both pathological response and outcome in LARC patients. ..
  5. del Puerto Nevado L, Marin Arango J, Fernandez Aceñero M, Arroyo Manzano D, Martinez Useros J, Borrero Palacios A, et al. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study. BMC Cancer. 2016;16:519 pubmed publisher